Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Becoming a Life Sciences Lawyer – The View From Goodwin (Chambers Associate)

Related Content

Chime Biologics and Daewoong Pharmaceutical Partner on Dupilumab Biosimilar

BIOSECURE Update – 1260H List Released

Supreme Court Declines to Review $220 Million Drug Pricing Judgment Against Eli Lilly

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

Polpharma and Tuteur Enter License for the Commercialization of a Biosimilar Targeting Autoimmune Diseases in Latin America

Samsung Bioepis Launches OPUVIZ in Europe

Amneal and Kashiv File IPR Petition on Omalizumab Patent

ICC Arbitration Rules Effective June 1, 2026: Key Changes and Practical Takeaways for Parties and Counsel

The Legal 500 US 2026 Recognizes 47 Goodwin Practices and 185 Lawyers

Innovafeed is Scaling Up and Entering a New Growth Phase Backed by a €51 Million Funding Round

Goodwin Advises SonoThera on Oversubscribed $125 Million Series B Financing

Goodwin Advises Nurix Therapeutics on Global Collaboration With Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg for $700 Million Upfront and Up to $2.3 Billion in Total

Goodwin Strengthens Life Sciences Public M&A Bench With Partner Richard Schwartz

Chambers USA 2026 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

Goodwin Advises Incyte in Expanded Molecular AI Collaboration and License Agreement With Genesis Valued at More Than $1 Billion

Goodwin Advises Ascidian Therapeutics on a Global Research Collaboration with Eli Lilly for Up To $1.9 Billion

Life Sciences

Intellectual Property